Leukemia, T-cell, Chronic - 25 Studies Found
Active, not recruiting |
: KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) : Adult T-cell Leukemia-Lymphoma : 2012-06-19 :
|
Completed |
: Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma : Acute T-Cell Leukemia-Lymphoma : 2003-05-20 : Biological: Alemtuzumab Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 follo |
Active, not recruiting |
: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia : Adult T-Cell Leukemia (ATL) : 2009-06-17 :
|
Completed |
: Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma : Adult T-cell Leukemia-lymphoma : 2009-06-09 : Biological: KW-0761 KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at |
Completed |
: Lenalidomide in HTLV-1 Adult T-Cell Leukemia : Adult T Cell Leukemia/Lymphoma : 2011-01-10 : Drug: Lenalidomide 25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cyc |
Active, not recruiting |
: A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma : Adult T-Cell Leukemia-Lymphoma : 2012-11-07 : Drug: Lenalidomide 25 mg of Lenalidomide administered orally once daily |
Recruiting |
: Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma :
: 2016-04-10 :
|
Completed |
: A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma :
: 2010-07-22 : Drug: Lenalidomide Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily o |
Completed |
: A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) :
: 2005-09-01 :
|
Completed |
: A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma :
: 2011-05-12 :
|